REACH testing requirements must not be driven by reproductive toxicity testing in animals

Alternatives to Laboratory Animals

Volumn 34, Issue 4, 2006, Pages 365-366

  Spielmann, Horst ^a   Vogel, Richard ^a  

^a FEDERAL INSTITUTE FOR RISK ASSESSMENT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

THALIDOMIDE;

CARCINOGENICITY; CHEMICAL ANALYSIS; COMPUTER MODEL; DRUG SAFETY; EDITORIAL; EMBRYOTOXICITY; EUROPEAN UNION; HEALTH CARE POLICY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MEDICAL INFORMATION; MEDICAL SOCIETY; MEDICOLEGAL ASPECT; MUTAGENICITY; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REPRODUCTIVE TOXICITY; RISK ASSESSMENT; TERATOLOGY; TOXICITY TESTING;

ANIMALIA;

EID: 33748523021     PISSN: 02611929     EISSN: None     Source Type: Journal    
DOI: 10.1177/026119290603400405     Document Type: Editorial

References (3)

1. Pedersen, F., de Bruijn, J., Munn, S. & van Leeuwen, K. (2003). Assessment of additional testing needs under REACH - effects of QSAR, risk based testing and voluntary industry initiatives. 33pp. JRC Report EUR 20863.
2. Bailey, J., Knight, A. & Balcombe, J. (2005). The future of teratology is in vitro. Biogenic Amines 19, 97-145.
3. Schaefer, C., Spielmann, H. & Vetter, K. (2006). Arzneiverordnung in Schwangerschaft und Stillzeit (Drug Therapy in Pregancy and Lacation), 7th Ed., 480pp. Elsevier/Urban & Fischer, in press.